Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3′‐sulfoquinovosyl‐1′‐monoacylglycerol, targeting angiogenesis

We previously reported that 3′‐sulfoquinovosyl‐1′‐monoacylglycerol (SQMG) was effective in suppressing the growth of solid tumors due to hemorrhagic necrosis in vivo. In the present study, we investigated the antiangiogenic effect of SQMG. In vivo assessment of antitumor assays showed that some tumor cell lines, but not others, were sensitive to SQMG. Microscopic study suggested that in SQMG‐sensitive tumors, but not SQMG‐resistant tumors, angiogenesis was reduced. We next investigated gene expression relating to angiogenesis in tumor tissues by quantitative real‐time polymerase chain reaction. Consequently, although vascular endothelial growth factor gene expression was not detected with significant differences among the cases, significant downregulation of Tie2 gene expression was observed in all SQMG‐sensitive tumors as compared with controls, but not in SQMG‐resistant tumors. These data suggested that the antitumor effects of SQMG could be attributed to antiangiogenic effects, possibly via the downregulation of Tie2 gene expression in SQMG‐sensitive tumors. (Cancer Sci 2008; 99: 1063–1070)

[1]  B. Olsen,et al.  Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling. , 2006, Experimental cell research.

[2]  K. Sakaguchi,et al.  Alpha-sulfoquinovosylmonoacylglycerol is a novel potent radiosensitizer targeting tumor angiogenesis. , 2006, Cancer research.

[3]  K. Yamaguchi,et al.  Loss of Tie2 receptor compromises embryonic stem cell-derived endothelial but not hematopoietic cell survival. , 2006, Blood.

[4]  Peter Carmeliet,et al.  Angiogenesis in life, disease and medicine , 2005, Nature.

[5]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[6]  Napoleone Ferrara,et al.  Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. , 2005, Cancer research.

[7]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[8]  Yi Wei,et al.  Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1). , 2004, Genes & development.

[9]  Patrick England,et al.  A short synthetic peptide inhibits signal transduction, migration and angiogenesis mediated by Tie2 receptor , 2004, EMBO reports.

[10]  D. Voskas,et al.  Inhibition of Tie-2 Signaling Induces Endothelial Cell Apoptosis, Decreases Akt Signaling and Induces Endothelial Cell Expression of the Endogenous Anti-Angiogenic Molecule, Thrombospondin-1 , 2004, Cancer biology & therapy.

[11]  N. Yang,et al.  Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. , 2003, Cancer research.

[12]  L. Ellis,et al.  Angiopoietin-1 inhibits vascular permeability, angiogenesis, and growth of hepatic colon cancer tumors. , 2003, Cancer research.

[13]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[14]  Siqing Shan,et al.  Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  M. Skobe,et al.  Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth. , 2002, The American journal of pathology.

[16]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[17]  K. Sakaguchi,et al.  Anti‐tumor Effect of Chemically Synthesized Sulfolipids Based on Sea Urchin's Natural Sulfonoquinovosylmonoacylglycerols , 2002, Japanese journal of cancer research : Gann.

[18]  T. Acker,et al.  Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor‐2 dominant‐negative receptor mutants , 2001, International journal of cancer.

[19]  G. Koh,et al.  Angiopoietin-1 induces endothelial cell sprouting through the activation of focal adhesion kinase and plasmin secretion. , 2000, Circulation research.

[20]  J. Kim,et al.  Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway. , 2000, Circulation research.

[21]  Dajun Yang,et al.  Angiopoietin-1 and its receptor Tie-2 participate in the regulation of capillary-like tubule formation and survival of endothelial cells. , 1999, Microvascular research.

[22]  T. Tsuruo,et al.  Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel. , 1999, Cancer research.

[23]  G. Martiny-Baron,et al.  Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vascular endothelial growth factor receptor pathway or the Tie-2 pathway. , 1999, Cancer research.

[24]  M. Dewhirst,et al.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Isner,et al.  Chemotactic Properties of Angiopoietin-1 and -2, Ligands for the Endothelial-specific Receptor Tyrosine Kinase Tie2* , 1998, The Journal of Biological Chemistry.

[26]  Urban Deutsch,et al.  Angiopoietin-1 induces sprouting angiogenesis in vitro , 1998, Current Biology.

[27]  M. Dewhirst,et al.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth. , 1997, The Journal of clinical investigation.

[28]  M. Dewhirst,et al.  Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. , 1997, Circulation research.

[29]  Douglas Hanahan,et al.  Signaling Vascular Morphogenesis and Maintenance , 1997, Science.

[30]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[31]  William Arbuthnot Sir Lane,et al.  Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth , 1997, Cell.

[32]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[33]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[34]  E. Morrisey,et al.  Structure and Expression of a Smooth Muscle Cell-specific Gene, SM22α (*) , 1995, The Journal of Biological Chemistry.

[35]  Lars Holmgren,et al.  Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinoma , 1994, Cell.

[36]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[37]  D. Dumont,et al.  The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. , 1993, Oncogene.

[38]  J. Rossant,et al.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors. , 1992, Oncogene.

[39]  J. Folkman.  What is the evidence that tumors are angiogenesis dependent? , 1990, Journal of the National Cancer Institute.

[40]  A. Ullrich,et al.  SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. , 1999, Cancer research.

[41]  G. Yancopoulos,et al.  The angiopoietins: Yin and Yang in angiogenesis. , 1999, Current topics in microbiology and immunology.

[42]  N. Takahashi,et al.  In vivo anti-tumour effect of 3'-sulphonoquinovosyl 1'-monoacylglyceride isolated from sea urchin (Strongylocentrotus intermedius) intestine. , 1997, British Journal of Cancer.